Holen Sie sich die Stockscreener-App
238.21
0.66%
1.57
Handel nachbörslich:
237.50
-0.71
-0.30%
Schlusskurs vom Vortag:
$236.64
Offen:
$237.8
24-Stunden-Volumen:
1.45M
Relative Volume:
1.12
Marktkapitalisierung:
$32.88B
Einnahmen:
$1.96B
Nettoeinkommen (Verlust:
$-253.24M
KGV:
-125.29
EPS:
-1.9012
Netto-Cashflow:
$94.06M
1W Leistung:
+0.46%
1M Leistung:
+20.17%
6M Leistung:
+48.74%
1J Leistung:
+40.81%
1-Tages-Spanne:
$234.63
$239.18
1-Wochen-Bereich:
$233.67
$240.18
52-Wochen-Spanne:
$125.38
$241.28
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
238.21 | 32.66B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
580.45 | 218.05B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.46 | 160.05B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.93 | 58.51B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
149.26 | 42.12B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
227.24 | 38.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera (NTRA): Valuation Check After ASH Signatera Lymphoma Data Fuels Hematology Growth Optimism - simplywall.st
NTRA: Double-digit MRD growth, broad Signatera adoption, and new clinical data drive future expansion - TradingView
Natera (NASDAQ: NTRA) to Present 144-Patient Lymphoma Signatera Data at ASH 2025 - Stock Titan
Morgan Stanley Raises Natera (NTRA) Price Target with Overweight Rating | NTRA Stock News - GuruFocus
Morgan Stanley assumes coverage on Natera stock with Overweight rating By Investing.com - Investing.com Nigeria
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium - Yahoo Finance
Morgan Stanley Raises Price Target on Natera to $265 From $220, Keeps Overweight Rating - MarketScreener
Have Insiders Sold Natera Shares Recently? - simplywall.st
Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins - Seeking Alpha
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool
Natera director Botha sells $17.7 million in stock By Investing.com - Investing.com Australia
Assessing Natera’s Value After 47.6% Rally and New Partnerships in 2025 - Yahoo Finance
How strong is Natera Inc. stock revenue growthQuarterly Market Summary & Accurate Entry/Exit Alerts - BỘ NỘI VỤ
Natera Director’s Multi-Million Dollar Stock Sale Shakes the Market - TipRanks
Natera director Botha sells $17.7 million in stock - Investing.com
Dir Botha Sells 75,000 ($17.7M) Of Natera Inc [NTRA] - TradingView
[Form 4] Natera, Inc. Insider Trading Activity - Stock Titan
Will Flatiron Partnership Give Natera (NTRA) a New Edge in OncoEMR Integration? - simplywall.st
Natera stock hits all-time high at 240.96 USD By Investing.com - Investing.com Canada
Natera stock hits all-time high at 240.96 USD - Investing.com
Evercore Gives Natera (NTRA) Outperform Rating - MSN
Key facts: JP Morgan raises Natera target; shares rise 2.9%; BV369 Trust to sell 75,000 shares - TradingView
JP Morgan Raises Price Target for Natera (NTRA) to $250 | NTRA S - GuruFocus
Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know - The Globe and Mail
Shareholder BV369 Trust Files To Sell 75,000 Of Natera Inc [NTRA] - TradingView
Natera (NTRA): Evaluating Valuation After Q3 Growth, Analyst Upgrades, and OncoEMR Integration - simplywall.st
Natera co-founder Sheena Jonathan sells $3.17 million in stock By Investing.com - Investing.com Nigeria
Natera director Baynes sells $2.8 million in shares By Investing.com - Investing.com Canada
Natera co-founder Sheena Jonathan sells $3.17 million in stock - Investing.com
Natera director Baynes sells $2.8 million in shares - Investing.com
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know - Finviz
Natera insider Form 4 details planned stock sales and holdings - Stock Titan
Dir Sheena Sells 14,000 ($3.2M) Of Natera Inc [NTRA] - TradingView
Natera Inc. (NTRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
First Week of July 2026 Options Trading For Natera (NTRA) - Nasdaq
Will Natera Inc. stock attract ESG investorsTrade Ideas & Safe Swing Trade Setup Alerts - newser.com
Trade Tracker: Stephanie Link buys Natera - MSN
Natera Inc.’s New Prenatal Test Study: A Potential Game-Changer in Genetic Screening - MSN
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.85%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):